MDS-336: Phase 2 Study of Pevonedistat + Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS

Bibliographic Details
Title:	MDS-336: Phase 2 Study of Pevonedistat + Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
Authors:	Watts, Justin, Adès, Lionel, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua, Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.
Source:	In Clinical Lymphoma, Myeloma and Leukemia September 2020 20 Supplement 1:S323-S324
Database:	ScienceDirect

More Details
ISSN:	21522650
DOI:	10.1016/S2152-2650(20)30981-2
Published in:	Clinical Lymphoma, Myeloma and Leukemia
Language:	English